Nabla Bio, a small startup founded by scientists from geneticist George Church’s lab at Harvard Medical School, has formed drug discovery collaborations with AstraZeneca, Bristol Myers Squibb and Takeda, the company told Endpoints News in an exclusive interview.
The startup is based on large language models developed in Church’s lab that predict protein structures. Nabla and its partners are building upon that AI research to design antibodies against proteins that have proven frustratingly difficult to drug with traditional methods.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.